Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment.

Osborne, Vicki; Davies, Miranda; Lane, Samantha; Evans, Alison; Denyer, Jacqueline; Dhanda, Sandeep; Roy, Debabrata; Shakir, Saad

Osborne, Vicki; Davies, Miranda; Lane, Samantha; Evans, Alison; Denyer, Jacqueline; Dhanda, Sandeep; Roy, Debabrata; Shakir, Saad.

Afiliação

Osborne V; Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, SO31 1AA, UK. vicki.osborne@dsru.org.
Davies M; School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK. vicki.osborne@dsru.org.
Lane S; Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, SO31 1AA, UK.
Evans A; School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK.
Denyer J; Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, SO31 1AA, UK.
Dhanda S; School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK.
Roy D; Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, SO31 1AA, UK.
Shakir S; School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK.

Drug Saf ; 43(8): 809-821, 2020 08.

Article em En | MEDLINE | ID: mdl-32578156

Assuntos

Infecções por Coronavirus; Pandemias; Pneumonia Viral; Ritonavir; Adulto; Betacoronavirus; COVID-19; Infecções por Coronavirus/tratamento farmacológico; Humanos; Lopinavir; Medição de Risco; SARS-CoV-2; Tratamento Farmacológico da COVID-19

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Infecções por Coronavirus / Ritonavir / Pandemias Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies / Systematic_reviews Limite: Adult / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google